Month: December 2021

Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, ‘Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis’

GENEVA, SWITZERLAND / ACCESSWIRE / December 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to...

Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack

To be Published in the International Journal of CardiologySEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a muscle...

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial Objective Response Rate (ORR) by Blinded Independent Central Review...

error: Content is protected !!